AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
-2.91%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$136M
AUM Growth
+$136M
(-18%)
Cap. Flow
-$37.2M
Cap. Flow
% of AUM
-27.37%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$1.14M |
| 2 |
Invesco QQQ Trust
QQQ
|
$1.02M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
$1.02M |
| 4 |
Amphastar Pharmaceuticals
AMPH
|
$1M |
| 5 |
Enovis
ENOV
|
$904K |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$16.7M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$2.31M |
| 3 |
UroGen Pharma
URGN
|
$2.16M |
| 4 |
Corcept Therapeutics
CORT
|
$2.14M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$1.5M |
Sector Composition
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $4.62M | 3.4% | 14,500 -1,500 | -9% | -$478K |
|
2
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.17M | 3.07% | 675,000 | – | – |
|
3
Rithm Capital
RITM
$6.57B
| $4.16M | 3.06% | 380,966 -40,000 | -10% | -$436K |
|
4
Pfizer
PFE
$141B
| $3.92M | 2.88% | 140,000 -35,000 | -20% | -$979K |
|
5
Harmony Biosciences
HRMY
$2.12B
| $3.68M | 2.71% | 122,000 | – | – |
|
6
Pacira BioSciences
PCRX
$1.2B
| $3.36M | 2.48% | 117,500 | – | – |
|
7
argenx
ARGX
$43.6B
| $3.12M | 2.3% | 7,250 -750 | -9% | -$323K |
|
8
Galapagos
GLPG
$2.07B
| $2.69M | 1.98% | 108,500 +3,500 | +3% | +$86.7K |
|
9
MGIC Investment
MTG
$6.42B
| $2.46M | 1.82% | 114,379 | – | – |
|
|
EFC
10
Ellington Financial
EFC
$1.36B
| $2.44M | 1.79% | 201,602 -20,000 | -9% | -$242K |
|
11
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.19M | 1.61% | 64,000 -30,000 | -32% | -$1.03M |
|
|
DX
12
Dynex Capital
DX
$1.64B
| $2.17M | 1.6% | 181,492 | – | – |
|
|
ONC
13
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.14M | 1.58% | 15,000 -1,750 | -10% | -$250K |
|
14
uniQure
QURE
$896M
| $2.06M | 1.52% | 460,000 | – | – |
|
15
Amicus Therapeutics
FOLD
$2.34B
| $2.01M | 1.48% | 202,500 +27,500 | +16% | +$273K |
|
16
DocGo
DCGO
$153M
| $2.01M | 1.48% | 650,000 | – | – |
|
|
RWT
17
Redwood Trust
RWT
$791M
| $1.87M | 1.38% | 288,343 | – | – |
|
|
MFA
18
MFA Financial
MFA
$1.05B
| $1.78M | 1.31% | 167,725 | – | – |
|
19
Celldex Therapeutics
CLDX
$1.47B
| $1.76M | 1.29% | 47,500 +9,000 | +23% | +$333K |
|
|
CERE
20
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.74M | 1.28% | 42,500 | – | – |
|
21
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $1.73M | 1.27% | 1,000,000 | – | – |
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.63M | 1.2% | 100,000 +55,000 | +122% | +$894K |
|
23
ArriVent BioPharma
AVBP
$776M
| $1.6M | 1.17% | 86,000 +3,000 | +4% | +$55.7K |
|
24
Royalty Pharma
RPRX
$15.6B
| $1.58M | 1.17% | 60,000 | – | – |
|
|
25
Invesco QQQ Trust
QQQ
$364B
| $1.56M | 1.15% | 3,257 +2,129 | +189% | +$1.02M |
|